Pharmaceutical Executive January 13, 2026
Mike Hollan

Key Takeaways

  • Merck is preparing for a patent cliff by focusing on 10 key programs, projected to generate $70 billion by the mid-2030s.
  • The company is actively pursuing business development, highlighted by the acquisition of Cidara Therapeutics to enhance its respiratory portfolio.
  • Phase 3 trials for Calderasib, a KRAS G12C inhibitor, are underway, aiming to improve outcomes for advanced NSCLC patients without intravenous chemotherapy.

CEO Rob Davis details specific funding forecasts for the company beyond Keytruda.

Merck’s chairman and CEO Rob Davis took the stage at the 44th annual JP Morgan Healthcare Conference in San Francisco to present a plan for the coming years and detail which programs have been successful for the company.1 Following the presentation, Dr....

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Related Articles:
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal

Share Article